Novo Nordisk AS has reduced the prices of its weight-loss drugs Ozempic and Wegovy in India, amidst an onslaught of copycat drugs in the world's third most overweight population.
The lowest doses of Ozempic and Wegovy in India will now be priced at ₹1,415 for a weekly shot, down from ₹2,200 and ₹2,712 earlier, respectively.
The new pricing brings the monthly cost for the lowest doses of both drugs to ₹5,660 from roughly ₹10-12,000.
The markdown comes 11 days after the Indian patent for semaglutide, the active pharmaceutical ingredient in the weight-loss drugs, expired in India.
By lowering prices, Novo Nordisk is attempting to retain patients who might otherwise migrate to local alternatives.
The price cuts are tiered across different dosage strengths, with Ozempic's 1 mg weekly shot now priced at ₹2,275, down 18.5%, and Wegovy's 0.5 mg dose seeing a 41.5% cut to ₹2,025.
